Lydia Montolio-Chiva Diego Carmona-Talavera Jose M López-Ortega Ana V Orenes-Vera Eduardo Flores-Fernández Juan J Alegre-Sancho
10.1177/03946320221115310
Int J Immunopathol Pharmacol
2022 Jan-Dec;36:3946320221115310.
anti-centromere antibodies anti-topoisomerase i antibodies immunological seroconversion nintedanib systemic sclerosis
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/35981966/
Autoantibodies Scleroderma, Systemic / complications Scleroderma, Systemic / drug therapy
Autoantibodies Scleroderma, Systemic / complications Scleroderma, Systemic / drug therapy Case Reports Female Humans Indoles / therapeutic use Rituximab / therapeutic use Autoantibodies Indoles Rituximab nintedanib
PMC9393658
35981966
Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report
2022